Welcome to our dedicated page for BeyondSpring Ordinary Shares news (Ticker: $BYSI), a resource for investors and traders seeking the latest updates and insights on BeyondSpring Ordinary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BeyondSpring Ordinary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BeyondSpring Ordinary Shares's position in the market.
BeyondSpring Inc. (NASDAQ: BYSI) announced a Research and Development (R&D) Day to discuss Plinabulin's potential as a cancer therapy and updates for SEED Therapeutics. Key Opinion Leaders will present on Plinabulin's immunomodulatory activity and unmet needs post immune-checkpoint-inhibitor failure. SEED Therapeutics updates will also be featured.
BeyondSpring, a biopharmaceutical company, reported positive results for 2023. The company dosed patients in Phase 2 trials for Plinabulin and Keytruda combinations, achieved milestones in molecular glue discovery, and made director appointments. SEED Therapeutics, a subsidiary, reached important pre-clinical milestones. The company's lead drug candidate, Plinabulin, showed promise in various studies, aiming to address unmet medical needs in cancer treatment. Financially, R&D and G&A expenses decreased, resulting in a net loss of $21.0 million for 2023.
BeyondSpring Inc. (NASDAQ: BYSI) has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the SEC, showcasing audited financial statements. The report can be accessed on the SEC's website and the company's site, offering hard copies to shareholders upon request.